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Summary
Chimeric antigen receptors (CARs) can mediate redirected lysis of tumour
cells in a major histocompatibility complex (MHC)-independent manner,
thereby enabling autologous adoptive T cell therapy for a variety of malig-
nant neoplasms. Currently, most CARs incorporate the T cell receptor (TCR)
CD3ζ signalling chain; however, the precise mechanisms responsible for
CAR-mediated T cell activation are unclear. In this study, we used a series of
immunoreceptor tyrosine-based activation motif (ITAM)-mutant and
transmembrane-modified receptors to demonstrate that CARs activate T
cells both directly via the antigen-ligated signalling chain and indirectly via
associated chains within the TCR complex. These observations allowed us to
generate new receptors capable of eliciting polyfunctional responses in
primary human T cells. This work increases our understanding of CAR func-
tion and identifies new avenues for the optimization of CAR-based therapeu-
tic interventions.
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Introduction
Chimeric antigen receptors (CARs) consist of a tumour-
associated antigen (TAA)-specific single chain variable frag-
ment (scFv) fused to a T cell-derived signalling chain. Gene-
modified T cells that express such receptors can be activated
by immobilized antigen and lyse tumour cells expressing
the cognate ligand in a major histocompatibility complex
(MHC)-unrestricted manner [1–3]. Accordingly, CAR-
based approaches are being explored for the treatment of
various cancers as alternatives to adoptive cell therapy using
patient-derived tumour-infiltrating or peripheral tumour-
reactive lymphocytes. Indeed, clinical trials are beginning to
show encouraging results [4], putting CARs on a par with
the more developed T cell receptor (TCR) gene transfer
regimens [5]. Many researchers in the CAR field have
adopted CD3ζ [6] as the chosen signalling domain for the
activating moiety. However, the mechanisms that underlie
CD3ζ-based CAR-mediated T cell activation are not
clear and structural distinctions suggest the possibility of
signalling pathways that deviate from those employed by
the endogenous TCR. A detailed understanding of CAR-
mediated signal transduction may therefore reveal new ways
to refine this therapeutic approach and optimize the devel-
opment of second-generation co-stimulatory receptors [7].
Many of the normal TCR-mediated signalling events are
known to take place during CAR-driven T cell activation,
including tyrosine phosphorylation of CD3ζ [8], recruit-
ment of ZAP70 [9], initiation of the mitogen-activated
protein kinase (MAPK) cascade [9] and induction of
nuclear factor of activated T cells (NFAT) [10]. It has also
been shown that a cytoplasmic domain-deficient CAR
containing the FcεRIγ chain can activate T cells via
heterodimerization with endogenous CD3ζ [11]. In addi-
tion, we have demonstrated that CAR–TCR interactions
and dimerization are a prerequisite for optimal CAR-driven
T cell activation [12]. These observations suggest that there
is cross-talk between the transgene-encoded CAR and
endogenous components of the T cell activation machinery.
In an effort to dissect CAR-mediated signalling mecha-
nisms and inform the strategic design of improved recep-
tors, we generated a series of mutant CARs with modified
intracellular signalling domains and/or transmembrane
domains [12]. These mutant receptors were used to show
that CARs can activate T cells directly (in cis) and indirectly
(in trans). The latter mechanism involved both the CAR
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dimerization partner and other components of the TCR
complex, enabling tailored truncations to the signalling
domain without significant loss of function. These observa-
tions have implications for the optimization of CAR expres-
sion and function.
Materials and methods
Antibodies
Anti-human CD3ε (UCHT1), anti-human CD3ζ (K25-
407·69), anti-human CD69 (FN50), anti-human TCRVβ8
(JR2), anti-mouse CD3ε (145-2C11), mouse IgG1 (MOPC-
31C), mouse IgG2b (MPC-11) and hamster immunoglobu-
lin (Ig)G1 (A19-3) phycoerythrin (PE) conjugates were
purchased from BD Biosciences (San Jose, CA, USA).
Sheep anti-mouse IgG-horseradish peroxidase (HRP)
(polyclonal), goat anti-human IgG-PE (polyclonal), mouse
anti-FLAG (M2) and mouse anti-FLAG-PE (M2) were pur-
chased from Sigma-Aldrich (St Louis, MO, USA). The fol-
lowing anti-human monoclonal antibodies (mAbs) were
used in polychromatic flow cytometry experiments: (i) anti-
CD4-PE-cyanin (Cy)5·5 (S3·5) and anti-CD8-QD705 (3B5)
(Life Technologies, Carlsbad, CA, USA); (ii) anti-interferon
(IFN)-γ-V450 (B27) (BD Horizon, BD Biosciences); and
(iii) anti-CD107a-fluorocein isothiocyanate (FITC)
(H4A3), anti-interleukin (IL)-2-allophycocyanin (APC)
(MQ1-17H12) and anti-tumour necrosis factor (TNF)-α-
PECy7 (Mab11) (BD Pharmingen, Franklin Lakes, NJ,
USA).
Generation of chimeric antigen receptor constructs
All CAR constructs used in this study contain the MFE23
anti-carcinoembryonic antigen (CEA) single chain antibody
[13]. The MFEζ CAR has been described previously [14].
MFE.htmζ consists of MFE23 fused to MHC class I trun-
cated extracellular and transmembrane domains (amino
acids 274–313) and the human CD3ζ cytoplasmic domain
(amino acids 32–142). MFEζ.C2G G-10C is a mutant form
of MFEζ with a displaced cysteine residue that permits pref-
erential homodimerization [12]. Introduction of immuno-
receptor tyrosine-based activation motif (ITAM) mutations
into the CAR constructs was carried out using a site-
directed mutagenesis kit (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions (primer details
available on request).
Cell lines
The following cell lines were used: (i) 293T (American Type
Culture Collection); (ii) Jurkat E6·1 (European Collection
of Cell Cultures); (iii) TCR-β-deficient Jurkat derivative
JRT3-T3·5, a kind gift from Dr Reno Debets (University
Medical Center, Rotterdam, the Netherlands); and (iv)
mouse MA5·8, a kind gift from Dr David Wiest (Fox Chase
Cancer Centre, Philadelphia, PA, USA). Jurkat and MA5·8
cells were maintained in T cell medium (TCM), comprising
RPMI supplemented with 10% heat-inactivated fetal calf
serum (FCS), 0·01 M HEPES, 1% L-glutamine and 0·1%
2-mercaptoethanol; 293T cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% FCS.
Retrovirus generation and lymphocyte transduction
The rKat retroviral vector system was used as described pre-
viously [15]. Retroviral supernatant was produced from
transiently transfected 293T cells using a modified calcium
chloride transfection protocol [13]. Medium from 293T
cells was passed through a 0·45 μm filter and used to infect
cells directly. Typically, 5 × 105 T cells were mixed with
retroviral supernatant and 6 μg/ml polybrene, then centri-
fuged for 3 h at 1200 g. Transductions were repeated on two
consecutive days.
Flow cytometric analysis and sorting
Transduction levels were assessed using CEA.hFc protein
generated from transiently transfected 293T cells, as
described previously [14]. Basic flow cytometric analysis
was conducted using either a FACScan or a FACSCalibur
flow cytometer (BD Biosciences) and WinMDI version 2·8
software. Polychromatic flow cytometric analysis was con-
ducted using a custom-modified FACSAriaII flow
cytometer (BD Biosciences) and FlowJo software version
9·5.3 (TreeStar Inc., Ashland, OR, USA). Cells were sorted
using either a FACSVantage or a FACSAria flow cytometer
(BD Biosciences) to obtain populations with equivalent
CAR surface expression (generally the top 5%). All cell
populations were >90% CAR+ after enrichment.
Polyacrylamide gel electrophoresis and
Western blotting
Cells were lysed in 1% CHAPS (3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulphonate) buffer [phosphate-
buffered saline (PBS), 1% CHAPS, 0·5% sodium
deoxycholate, 2% sodium dodecyl sulphate] containing
complete protease inhibitor cocktail tablets (Roche, Indian-
apolis, IN, USA) for 30 min, then centrifuged through
polymer wool to clear the supernatant. Protein concentra-
tions were established using a protein estimation kit (Bio-
Rad, Hercules, CA, USA). Reduced or non-reduced samples
containing 20 μg of total protein were separated on 10%
sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis (SDS-PAGE) gels, transferred to Hybond nitrocellu-
lose membranes (Amersham Biosciences, Pittsburgh, PA,
USA) and probed with mouse anti-human CD3ζ (BD
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Biosciences) followed by HRP-conjugated sheep anti-mouse
IgG (Sigma-Aldrich), both diluted 1:1000 in PBS-Tween/5%
skimmed milk powder. Bands were resolved using an ECL
Western Blotting Detection kit (Amersham Biosciences),
according to the manufacturer’s instructions, and the mem-
branes were analysed by exposure to X-ray film.
CD69 expression assay
Ninety-six-well flat-bottomed non-tissue culture plates
were coated overnight with the indicated concentrations of
CEA protein diluted in borate-buffered saline (0·015 M
sodium borate, 0·15 M sodium chloride, pH 8·5). The plates
were then blocked for 1–2 h at 37°C with 2% bovine serum
albumin (BSA)/PBS before addition of 1 × 105 CAR-
transduced T cells in 100 μl of TCM per well. After incuba-
tion for 24 h at 37°C, cells were stained with anti-CD69-PE
and analysed by flow cytometry.
Polyfunctionality assay
Plates were coated with CEA and blocked as above before
the addition of 3 × 105 CAR-transduced T cells per well in
the presence of brefeldin A (10 μg/ml; Sigma-Aldrich),
GolgiStop (0·7 μl/ml; BD Biosciences) and anti-CD107a-
FITC. After incubation for 6 h at 37°C, cells were washed in
FACS buffer (PBS/1% FCS) and incubated for 10 min at
room temperature with LIVE/DEAD® Fixable Aqua stain
(Life Technologies). Cells were then surface-stained with
anti-CD4-PECy5·5 and anti-CD8-QD705, washed twice in
FACS buffer, permeabilized using a Cytofix/Cytoperm kit
(BD Biosciences) and stained intracellularly with anti-
FLAG-PE, anti-IFN-γ-V450, anti-IL-2-APC and anti-TNF-
α-PECy7. Data were collected on a custom-modified
FACSAriaII flow cytometer and analysed with FlowJo soft-
ware version 9·5.3 (TreeStar Inc.). Graphics were generated
using the spice software suite [16].
Statistical analysis
Up-regulation of CD69 expression was analysed using a
Kruskall–Wallis test. Half maximal effective concentration
(EC50) values were compared using one-way analysis of
variance (anova). Significance levels are indicated as
*P < 0·05, **P < 0·01 and ***P < 0·001.
Results
Chimeric antigen receptors can activate T cells via their
heterodimerizing native CD3ζ partner
It has been demonstrated previously that CARs containing
the transmembrane region of FcεRIγ can mediate T cell
activation by heterodimerizing with CD3ζ [11]. This obser-
vation suggests that CAR-driven signalling pathways are
more complex than first thought. To determine whether the
same is true for CD3ζ-based CARs, we generated a panel of
receptors with defined interchain interactions. MFEζ con-
sists of the CEA-specific scFv MFE23 fused directly to the
CD3ζ signalling chain from the TCR complex, allowing
both homodimerization and heterodimerization with
endogenous CD3ζ [12]. MFEζ.C2G G-10C differs from
MFEζ in that the interchain disulphide bond has been
moved from the transmembrane C2 to the extracellular
G-10 position. The displaced disulphide bridge eliminates
heterodimerization with endogenous CD3ζ, but the capac-
ity to homodimerize and interact with the endogenous TCR
is maintained [12]. MFE.htmζ incorporates the human leu-
cocyte antigen (HLA)-A*02 transmembrane domain fused
to the CD3ζ cytoplasmic domain; this receptor can only
form monomers, and is unable to interact with the endog-
enous TCR complex [12]. We also generated identical
receptors with Y–F (Tyr–Phe) mutations at each ITAM
within the cytoplasmic domain, thus making them
signalling-deficient [17]. All receptors were cloned with a
C-terminal FLAG-tag to permit immunoblot and flow
cytometric detection.
Jurkat T cells were transduced with retroviral vectors
encoding the indicated CARs. Immunoblot analysis con-
firmed the presence of CAR heterodimers and homodimers
in MFEζ-expressing cells, homodimers and monomers in
MFEζ.C2G G-10C-expressing cells and monomers only
in MFE.htmζ-expressing cells (Fig. 1a). Cellular activation
in response to CEA was assessed using flow cytometry to
measure CD69 up-regulation. This analytical approach in
Jurkat T cells closely mirrors CAR-mediated activation via
‘signal 1’ in primary human T cells [12]. MFEζ and
MFEζ.C2G G-10C up-regulated CD69 most potently, fol-
lowed by MFE.htmζ. All three CARs induced significant
increases in CD69 expression at CEA concentrations of
1·0 μg/ml (Fig. 1b). The ITAM-mutant CARs responded in
the same relative order (MFEζ > MFEζ.C2G G-10C >
MFE.htmζ). This result confirms that MFEζ can mediate T
cell activation in a CAR-independent manner, presumably
via heterodimerization and potentially via interactions with
the TCR complex. The observation that MFEζ.C2G G-10C
Y–F up-regulated CD69 further suggests the existence of a
mechanism beyond heterodimerization with endogenous
CD3ζ.
To dissect this phenomenon further, the same experiment
was repeated in TCR-β-deficient Jurkat T cells (JRT3–T3·5).
These cells have a mutation in the TCR-β locus and, conse-
quently, do not express a complete surface TCR complex
[18]. They do, however, express CD3ζ. As in parental Jurkat
T cells, CAR-mediated up-regulation of CD69 followed the
relative order MFEζ > MFEζ.C2G G-10C > MFE.htmζ,
albeit with responses that appeared to be more sensitive
compared to the parental E6·1 cells. This latter observation
could reflect higher surface expression of CARs transduced
into the JRT3–T3·5 line or intrinsic differences in cellular
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sensitivity to stimulation. The only ITAM-mutant CAR to
show any significant activity was MFEζ Y–F (Fig. 1c). This
finding suggests that the primary trans-activatory mecha-
nism underlying CAR-driven T cell activation occurs via
endogenous CD3ζ. However, other components of the TCR
are also implicated by the observation that MFEζ.C2G
G-10C Y–F lost all activity in this system.
Chimeric antigen receptor-mediated trans-activation is
favoured by interactions with the TCR
To elucidate the role of TCR trans-signalling events, we con-
ducted the same experiment in the MA5·8 cell line, which
expresses all components of the TCR complex except CD3ζ
[19]. These cells express low levels of the endogenous TCR,
which is up-regulated in response to CD3ζ-based CAR
expression; the magnitude of this effect is related to the
strength of the CAR–TCR interaction [12,20]. MFEζ
(± Y–F) up-regulated TCR expression to the greatest extent,
as established by measurement of surface CD3ε, followed by
MFEζ.C2G G-10C (± Y–F). In contrast, MFE.htmζ (± Y–F)
was unable to rescue surface TCR expression (Fig. 2a). As
in the Jurkat system, all receptors with intact ITAMs
up-regulated CD69 robustly in response to immobilized
CEA. Interestingly, we found that MFEζ Y–F and
MFEζ.C2G G-10C Y–F induced significant (P < 0·05)
increases in CD69 expression, despite the absence of func-
tional CAR ITAMs and endogenous CD3ζ (Fig. 2b).
MFE.htmζ failed to up-regulate CD69 expression. These
results suggest that CARs can mediate T cell activation via
interactions with the endogenous TCR.
Trans-activation permits tailored truncations to
chimeric antigen receptor signalling domains
The data presented above indicate that CARs activate T cells
via multiple mechanisms, the relative potency of which
appears to follow the order cis-signalling > CD3ζ trans-
signalling > TCR trans-signalling. This led us to hypothesize
that we could reduce the size of the cytoplasmic domain
without a concomitant loss of signalling capacity. Previous
work has shown that the order of ITAM phosphorylation is
crucial for T cell activation, such that the membrane-
proximal first ITAM is required for phosphorylation of the
adjacent signalling motifs [21]. Accordingly, we progres-
sively truncated MFEζ from the C-terminal third ITAM.
The antigen responsiveness of these ITAM-truncated CARs
was assessed in transduced Jurkat T cells as above. Interest-
ingly, we found that potency was largely unaffected by the
lack of the third ITAM. Truncation of the second ITAM,
however, reduced antigen responsiveness (Fig. 3a). Recep-
tors lacking all three ITAMs were profoundly impaired in
functional terms compared to the wild-type receptor, an
observation akin to that seen with the ITAM-mutant recep-
tors tested in Fig. 1. These differences were reflected in
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Fig. 1. Immunoreceptor tyrosine-based activation motif
(ITAM)-mutant chimeric antigen receptors retain a spectrum of
functional activity in Jurkat E6·1 and JRT3-T3·5 cells –Jurkat E6·1
cells were transduced with retroviral constructs encoding the indicated
chimeric antigen receptors (CARs) and sorted by flow cytometry to
obtain enriched populations of CAR+ cells. CAR+ cells were lysed and
subjected to sodium dodecyl sulphate-polyacrylamide gel
electophoresis (SDS-PAGE). Transferred proteins were detected using
an anti-FLAG monoclonal antibody (mAb). Reducing and
non-reducing conditions are shown with molecular weight (KDa)
markers (a). Transduced Jurkat E6·1 (b) or JRT3-T3·5 (c) cells were
assessed for surface expression of the T cell activation marker CD69
after stimulation for 24 h with the indicated concentrations of
immobilized carcinoembryonic antigen (CEA) protein. Significant
increases in CD69 expression between 0 μg/ml and 1·0 μg/ml are
shown as *P < 0·05, **P < 0·01 and ***P < 0·001 (Kruskal–Wallis test).
For activation assays (b,c), arithmetic means of three independent
experiments ± standard deviation are shown. NT: non-transduced.
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measurements of antigen sensitivity, with receptors contain-
ing no ITAMs or just a single ITAM having significantly
higher EC50 values compared to the wild-type receptor
(P < 0·001 and P < 0·05, respectively) (Fig. 3b).
To confirm these observations, we transduced primary
human T cells from three healthy donors with receptors
containing no, one, two or three ITAMs. After in-vitro
expansion, we activated these transduced cells with immo-
bilized CEA and measured intracellular cytokine produc-
tion and CD107a mobilization by flow cytometry (Fig. 4
and Supporting information, Fig. S1). Regardless of the
number of ITAMs, all of the CARs tested elicited all four
measured functions in response to CEA stimulation. As
expected, response magnitude and antigen sensitivity for
the majority of functional readouts followed the hierarchy
observed in Jurkat cells, with CAR efficacy dictated by the
number of ITAMs. Notably, some functions were impacted
more by the loss of ITAMs than others; in addition, this
effect varied with T cell lineage. The production of IL-2
appeared to be most sensitive to the loss of ITAMs, espe-
cially in CD4+ cells. Furthermore, in two of the three donors
tested, the three-ITAM receptor was not optimal for
CD107a mobilization in CD8+ cells. Greater frequencies of
CD8+ cells responded to CAR-mediated antigen recognition
compared to CD4+ cells, particularly with regard to IFN-γ
production.
To ascertain antigen sensitivity, we calculated EC50 values
for each function (Fig. 5). Although the maximum response
elicited by each receptor varied, we found few differences in
terms of antigen sensitivity. Compared to the three-ITAM
receptor, the only significant differences in EC50 values were
observed for CD107a in CD8+ cells (three-ITAM versus no
ITAM, P < 0·01), TNF-α in CD4+ cells (three-ITAM versus
no ITAM, P < 0·01; three-ITAM versus one/two-ITAM,
P < 0·05) and TNF-α in CD8+ cells (three ITAM versus no
ITAM P < 0·05). In addition, we analysed the functional
profiles of CAR-transduced T cells using spice soft-
ware [16]. All CARs tested displayed dose-dependent
polyfunctionality profiles within both the CD4+ and CD8+
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Fig. 2. Residual chimeric antigen receptor cis- and trans-signalling
mechanisms permit activity in CD3ζ-deficient MA5·8 cells –
CD3ζ-deficient MA5·8 cells were transduced with the indicated
chimeric antigen receptors (CARs) and enriched for expression. CD3ε
surface expression was measured to evaluate CAR–T cell receptor
(TCR) interactions (a). Transduced MA5·8 cells were assessed for
surface expression of CD69 after stimulation for 24 h with the
indicated concentrations of immobilized carcinoembryonic antigen
(CEA) protein (b). Significant increases in CD69 expression between
0 μg/ml and 1·0 μg/ml are shown as *P < 0·05, **P < 0·01 and
***P < 0·001 (Kruskal–Wallis test). Arithmetic means of three
independent experiments ± standard deviation are shown. NT:
non-transduced.
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(ITAM)-truncated chimeric antigen receptors retain functional
capacity in Jurkat E6·1 cells – Jurkat E6·1 cells were transduced with
the indicated full-length and truncated MFEζ variants and enriched
for expression. Transduced cells were assessed for surface expression
of CD69 after stimulation for 24 h with the indicated concentrations
of immobilized carcinoembryonic antigen (CEA) protein (a) and
EC50 values were compared by one-way (anova) (b). *P < 0·05,
**P < 0·01 and ***P < 0·001. Arithmetic means of three independent
experiments ± standard deviation are shown. NT: non-transduced.
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lineages (Fig. 6). Notably, polyfunctionality was more
obvious in CD8+ cells compared to CD4+ cells (Fig. 6a,b).
Furthermore, there appeared to be a gradual decrease in
polyfunctionality at intermediate CEA concentrations as
the CARs were progressively truncated, particularly when
the final ITAM was removed (Fig. 6b,d). The primary func-
tion elicited in CD8+ cells was TNF-α production. A large
proportion of CD8+ cells were positive for TNF-α plus
CD107a and/or IFN-γ. However, only a fraction of cells elic-
ited all four effector functions (Fig. 6b). The majority of
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Fig. 5. Immunoreceptor tyrosine-based activation motif (ITAM)-truncated chimeric antigen receptors do not show significant variations in antigen
sensitivity for most effector functions in CD4+ and CD8+ T cell lineages – T cells from three healthy donors were transduced with the indicated
chimeric antigen receptors (CARs) and expanded in vitro. Transduced CD4+ and CD8+ cells, identified by FLAG expression, were assessed for
CD107a mobilization and intracellular production of interferon (IFN)-γ, tumour necrosis factor (TNF)-α and interleukin (IL)-2 after stimulation
for 6 h with the indicated concentrations of immobilized carcinoembryonic antigen (CEA) protein. EC50 values were calculated using GraphPad
Prism software and compared by one-way analysis of variance (anova). *P < 0·05, **P < 0·01 and ***P < 0·001 compared to three ITAM.
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CD4+ cells elicited only a single function (primarily TNF-
α); very few elicited two, three or four effector functions
(Fig. 6d).
Together with the observations made in Jurkat cells, these
data suggest that the third ITAM is largely dispensable for
CAR function. Further truncations, however, can have a
negative impact on certain effector functions.
Discussion
There is growing enthusiasm for the use of adoptively
transferred immune cells in the treatment of cancer. In
part, this is driven by promising work conducted with
gene-modified T cells engrafted with tumour-reactive
TCRs [5]. Synthetic receptors, such as CARs, circumvent
the requirement of TCRs for MHC restriction, a feature
that expands their potential use in tailored cancer thera-
pies. It is important, therefore, to establish the mechanisms
that underlie CAR-mediated T cell activation. Previously,
we showed that CAR–TCR interactions enhance CAR-
driven activation of transduced T cells. However, the
mechanistic basis for this effect was not elucidated. In par-
ticular, it was not clear whether the interacting TCR
complex was functioning as a distinct signalling unit or
3 ITAM
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1 ITAM
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2 ITAM
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(a)
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(d)
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0·031250 0·0625 0·125 0·25 0·5 1
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Fig. 6. Immunoreceptor tyrosine-based
activation motif (ITAM)-truncated chimeric
antigen receptors elicit polyfunctional responses
in CD4+ and CD8+ T cell lineages – T cells from
three healthy donors were transduced with the
indicated chimeric antigen receptors (CARs)
and expanded in vitro. Transduced CD4+ and
CD8+ cells, identified by FLAG expression,
were assessed for CD107a mobilization and
intracellular production of interferon (IFN)-γ,
tumour necrosis factor (TNF)-α and interleukin
(IL)-2 after stimulation for 6 h with the
indicated concentrations of immobilized
carcinoembryonic antigen (CEA) protein. The
functional profiles of CD8+ (a,b) and CD4+
(c,d) cells were analysed using spice software.
Pie charts depict the number of functions as
follows: grey, 0; blue, 1; green, 2; yellow, 3; red,
4. Arc graphs indicate the proportion of cells
with each combination of effector functions for
each CAR (from left to right: three ITAM, two
ITAM, one ITAM and no ITAM) at a CEA
concentration of 0·125 μg/ml for CD8+ (b) and
CD4+ (d) cells.
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simply facilitating T cell activation in an indirect manner.
The present study demonstrates that the TCR complex
does indeed act as an independent signalling unit for
CAR-driven T cell activation, co-ordinating with signals
mediated by the CAR itself and the native CD3ζ signalling
chain. Accordingly, the molecular events downstream of
CAR ligation are more complex than initially anticipated.
Indeed, the ability of CD3ζ-based CARs to interact with
components of the TCR complex permits targeted trunca-
tions of the signalling chain without undue functional
consequences.
Our observations lead to an important question. How do
CAR molecules actually transmit signals across the mem-
brane? This issue remains unresolved even for native TCRs.
Currently popular torsion-based models have given rise to
the idea that the TCR is a mechanosensor [22]. Such models
permit conformational changes in the ionically interacting
CD3 chains that favour their phosphorylation. In contrast,
our data suggest that the opposite is true for CAR-driven T
cell activation; i.e. conformational changes in CD3ζ induce
structural deformation of other components of the TCR
complex. Alternatively, antigen-mediated clustering of
CARs may allow phosphorylation of the TCR complex by
src kinases. The conformational change model of CD3ζ sig-
nalling is supported by our recent observation that CAR
function is seriously impaired when the highly vibrational
transmembrane L9 residue is mutated [12,23,24]. This
hypothesis, whereby activation is driven by conjugation of
one of the CD3 chains, is not unrealistic. Indeed, it is in
essence the mechanism that underlies the activation of
T cells by mitogenic antibodies such as OKT3 and UCHT1
[25].
In agreement with a previous study [17], we found that
deleting the third ITAM had little effect on the overall func-
tion of CD3ζ chimeras. Conversely, both Chae et al. and
Geiger et al. [17,26] demonstrated that a greater functional
deficit accompanied the loss of the two C-terminal ITAMs.
However, neither of these studies would have taken
heterodimerization into account due to the use of CD8 and
MHC class I transmembrane domains. The maintenance of
CAR function in the absence of the third ITAM may explain
why the FCεRIγ signalling subunit, which contains just two
ITAMs, has proved to be a useful alternative to CD3ζ in a
number of studies [27,28]. Removing the C-terminal ITAM
from the introduced CAR may also reduce CD3ζ-mediated
apoptosis, as demonstrated by Lenardo and colleagues [29].
The effects of ITAM removal are likely to be less obvious
in our system due to the aforementioned capacity to
heterodimerize, which compensates to some extent for the
lost signalling capacity. However, the key point is that CAR
size can be reduced without loss of function. Together with
our recent work identifying a role for TCR–CAR interac-
tions in optimal CAR function, these results highlight the
importance of using the CD3ζ transmembrane domain as a
component of CARs. In addition, we show here that the
capacity of CD3ζ transmembrane-bearing CARs to interact
with the TCR complex enables signalling in a CD3ζ-
independent manner. Further work is required to determine
which components of the TCR are important for this
function.
Although IL-2 production appears to be the function
most affected by ITAM loss, this does not impinge upon the
primary objective of first generation CARs. Indeed, CD28
has a largely synergistic effect on IL-2 production mediated
by the TCR. Thus, ITAM-mutant second-generation CARs
containing the CD28 signalling module may not show any
functional compromise in terms of IL-2 production. A
caveat to this may be the use of second generation receptors
incorporating the CD3ζ transmembrane region which,
although tested and published, have not been compared
critically to existing receptors [30].
Herein, we report a comprehensive analysis of T cell
effector function elicited by CAR-mediated antigen recogni-
tion. Polyfunctional response profiles were observed with
both intact and ITAM-truncated CARs, more noticeably in
CD8+ cells compared to CD4+ cells. This latter phenomenon
might reflect differential lineage-specific activation thresh-
olds. Alternatively, it could hinge upon the amount of free
Lck available for CAR-mediated activation. Indeed, Lck has
been shown to associate preferentially with CD4 compared
to CD8 [31], potentially restricting its availability in CD4+ T
cells. Strategies that enhance the polyfunctional effector
profiles of CD4+ T cells may therefore improve the efficacy
of CAR therapy, particularly as it has been established that
CAR-engrafted CD4+ T cells play a crucial role in tumour
eradication [2].
In summary, we show here that CARs incorporating the
CD3ζ transmembrane domain can signal via endogenous
CD3ζ as well as via other undefined components of
the TCR complex. This observation led us to demonstrate
that CARs with truncated cytoplasmic domains can still
function in both Jurkat T cells and primary human
T cells, eliciting polyfunctional profiles in both the CD4+
and CD8+ lineages. Rather than activation being dependent
upon a stoichiometrically equal ratio of CAR to antigen,
it seems more likely that the various signalling chains
involved upon CAR binding permit one antigen to mediate
a network of interchain phosphorylation events. Such a
process would explain the high antigen sensitivity of
CARs. Moreover, the cross-talk is efficient enough for
ITAMs to be deleted from the signalling chain without con-
comitant functional impairments. This is an important
observation because it means that the size of the transgene,
or at least the size of the CD3ζ component of next genera-
tion CARs, can be reduced without incurring therapeuti-
cally relevant loss of function. Such observations open
avenues for tailoring the cytoplasmic domain of CARs,
removing unnecessary components and in turn replacing
them with motifs that enhance both expression and
function.
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